Edition:
United States

Urogen Pharma Ltd (URGN.OQ)

URGN.OQ on NASDAQ Stock Exchange Global Market

36.80USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$36.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
28,181
52-wk High
$44.38
52-wk Low
$13.01

Chart for

About

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for... (more)

Overall

Beta: --
Market Cap(Mil.): $484.97
Shares Outstanding(Mil.): 13.18
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 190.77 15.47
EPS (TTM): -- -- --
ROI: -- -11.61 33.71
ROE: -- -35.87 16.38

BRIEF-Urogen Pharma Q3 loss per share $0.02

* Urogen Pharma reports third quarter 2017 financial results and recent corporate developments

Nov 14 2017

BRIEF-Menora Mivtachim reports 5.38 pct passive stake in UroGen Pharma ‍​

* Menora Mivtachim Holdings Ltd reports 5.38 percent passive stake in UroGen Pharma Ltd as of Nov 1 - SEC filing ‍​ Source: (http://bit.ly/2hdmj4k) Further company coverage:

Nov 08 2017

BRIEF-Urogen Pharma receives FDA fast track designation for Mitogel

* Urogen Pharma receives FDA fast track designation for Mitogel for the treatment of upper tract urothelial carcinoma (UTUC)

Aug 29 2017

BRIEF-UroGen Pharma Q2 loss per share $0.70

* UroGen Pharma reports second quarter 2017 financial results and recent corporate developments

Aug 14 2017

BRIEF-Jay Moorin reports a 11.5 pct passive stake in Urogen Pharma

* Jay Moorin reports a 11.5 percent passive stake in Urogen Pharma Ltd as of May 9, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2ufDxWd) Further company coverage:

Jul 20 2017

BRIEF-Allergan submits investigational NDA for rtgel in combination with botox

* Investigational new drug application for rtgel™ in combination with botox® for the treatment of overactive bladder submitted to FDA by Allergan

Jul 19 2017

Earnings vs. Estimates